Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2024 07:00 ET | Source: IN8bio, Inc

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 05, 2024 09:00 ET | Source: IN8bio, Inc

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
October 01, 2024 08:00 ET | Source: IN8bio, Inc

IN8bio Announces Pricing of $12.4 Million Private Placement

IN8bio Announces Pricing of $12.4 Million Private Placement
September 04, 2024 16:01 ET | Source: IN8bio, Inc

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
August 29, 2024 06:05 ET | Source: IN8bio, Inc

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 12, 2024 08:05 ET | Source: IN8bio, Inc

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio Announces FDA Guidance for Registrational Trial of INB-100 as 100% of AML Patients remain in Complete Remission
August 08, 2024 16:05 ET | Source: IN8bio, Inc

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
June 24, 2024 08:00 ET | Source: IN8bio, Inc

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...
June 13, 2024 16:01 ET | Source: IN8bio, Inc

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 03, 2024 06:05 ET | Source: IN8bio, Inc

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right